Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.
作者： Mitsuo Katano , Norihiro Koya , Masayo Umebayashi , Akifumi Kiyota , Hideya Onishi
DOI:
关键词:
摘要: Aim: We explored the possibility of combining adoptive immunotherapy with cytokine-activated killer (CAK) cells and epidermal growth factor receptor monoclonal antibody, cetuximab, as a treatment for cholangiocarcinoma. Materials Methods: CAK were cultured high- dose interleukin-2 anti-CD3 antibodies. This cell population contained both activated CD16 + /CD56 (NK) CD3 /NKG2D high+ T-cells. The effect alone in combination, on viability human cholangiocarcinoma was evaluated. Results: Culture alone, but not cetuximab exhibited modest cytotoxicity toward cells. However, significantly enhanced cytotoxicity. enhancement inhibited by addition excess immunoglobulins, suggesting that antibody-dependent cytotoxicity, mediated NK culture involved this mechanism. Conclusion: Cetuximab may be used to enhance therapeutic activity patients cholangiocarcinoma, potentiating cellular Cholangiocarcinoma (CC) originates from neoplastic
elsevier.com参考文章(29)
Evelyne Loyer, Karen R. Eckmann, Julian H. Slade, Harmeet Kaur, Andrea Landgraf, Jacqueline M. Weatherly, E. Lin, Dina K. Patel, Milind Javle, Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointestinal cancer research : GCR. ,vol. 4, pp. 155- 160 ,(2011)
Sandilands Gp, Crawford Rj, Templeton G, MacSween Rn, Lucie N, Cocker Je, Atrah Hi, In vivo and in vitro blocking of human lymphocyte Fc gamma-receptors by intravenous gammaglobulin. Journal of clinical & laboratory immunology. ,vol. 23, pp. 109- 115 ,(1987)
Mobin Karimi, Thai M. Cao, Jeanette A. Baker, Michael R. Verneris, Luis Soares, Robert S. Negrin, Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. Journal of Immunology. ,vol. 175, pp. 7819- 7828 ,(2005) , 10.4049/JIMMUNOL.175.12.7819
Yasser Shaib, Hashem El-Serag, The epidemiology of cholangiocarcinoma. Seminars in Liver Disease. ,vol. 24, pp. 115- 125 ,(2004) , 10.1055/S-2004-828889
D Yoshikawa, H Ojima, A Kokubu, T Ochiya, S Kasai, S Hirohashi, T Shibata, Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma British Journal of Cancer. ,vol. 100, pp. 1257- 1266 ,(2009) , 10.1038/SJ.BJC.6604988
Michael R. Verneris, Mobin Karami, Jeanette Baker, Anishka Jayaswal, Robert S. Negrin, Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. ,vol. 103, pp. 3065- 3072 ,(2004) , 10.1182/BLOOD-2003-06-2125
Jan Harder, Oliver Waiz, Florian Otto, Michael Geissler, Manfred Olschewski, Brigitte Weinhold, Hubert E Blum, Annette Schmitt-Graeff, Oliver G Opitz, EGFR and HER2 expression in advanced biliary tract cancer. World Journal of Gastroenterology. ,vol. 15, pp. 4511- 4517 ,(2009) , 10.3748/WJG.15.4511
Kory L. Alderson, Paul M. Sondel, Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity BioMed Research International. ,vol. 2011, pp. 379123- 379123 ,(2011) , 10.1155/2011/379123
Tianqian Zhang, Dorothee Herlyn, Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer Cancer Immunology, Immunotherapy. ,vol. 58, pp. 475- 492 ,(2009) , 10.1007/S00262-008-0598-Y
Raphaël Maréchal, Jef De Schutter, Nathalie Nagy, Pieter Demetter, Arnaud Lemmers, Jacques Devière, Isabelle Salmon, Sabine Tejpar, Jean-Luc Van Laethem, None, Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer. ,vol. 10, pp. 340- 340 ,(2010) , 10.1186/1471-2407-10-340